Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | SDCBP | O00560 | 1/20 | 0.34 |
| ▸ | SDC2 | P34741 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151029 | 0.78 | ADORA2A (0.33) | — | |
| SCHEMBL7047603 | 0.78 | ELANE (0.40) | ALDH1A1KDM4E | |
| SCHEMBL5293859 | 0.78 | ELANE (0.31) | — | |
| SCHEMBL29860755 | 0.75 | NR4A2 (0.32) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL3219793 | 0.75 | ADORA2A (0.36) | ALDH1A1GAASMN1; SMN2KDM4E | |
| SCHEMBL1965199 | 0.72 | ADORA3 (0.43) | MAPTALDH1A1GAALMNAHPGD | |
| SCHEMBL26696395 | 0.72 | ALDH1A1 (0.40) | MAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL10679044 | 0.71 | GRM5 (0.36) | LMNAHPGDKDM4EKMT2A | |
| SCHEMBL2596200 | 0.70 | PTGS2 (0.41) | LMNATSHR | |
| SCHEMBL3236321 | 0.69 | LMNA (0.41) | MAPTALDH1A1GAALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132420-B2 | Aspartic protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1140846-B1 | ASPARTIC PROTEASE INHIBITORS | US GOV HEALTH & HUMAN SERV (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050090546-A1 | Aspartic protease inhibitors | GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-04-28 | — | — | US | disclosed |
| US-6613764-B1 | Compounds such as N,N-dibenzylphenylalanine benzyl ester, used as enzyme inhibitors; prophylaxis of lymphadenopathy associated virus, cancer and malaria | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-09-02 | — | — | US | disclosed |
| EP-1140846-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040558-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090546-A1 | Aspartic protease inhibitors | DPP7, SENP7, DNPEP | MAPT 3730/4885CFD 938/4885ALDH1A1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.